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Numerous recent studies describe the strong association between tumor-infiltrating lymphocytes (TILs) and patient survival in human cancer. 1 Although most studies focus on CD8 + T cells, other lymphocyte subsets also contribute to this effect. Here, we briefly describe the roles of CD20 + tumor-infiltrating B cells (CD20 + TILs), which are strongly associated with favorable outcomes in breast, lung, ovarian and cervical cancer. 2 It is easy to rationalize the prognostic effect of CD8 + TILs, given their direct cytolytic activity against tumor cells. But how might CD20 + TILs promote tumor immunity? We recently investigated this issue in high-grade serous ovarian cancer (HGSC), 3 a setting where we had previously shown that CD20 + TILs are strongly associated with survival. 4 First, we demonstrated that CD20 + TILs display characteristics of antigenexperienced, oligoclonal B cells. This is in contrast with the polyclonal mixture of naïve and memory cells that would be expected if B cells simply were irrelevant bystanders in the tumor environment. Specifically, we showed that CD20 + TILs express cell surface IgG, indicating that they have undergone class switching. Moreover, we sequenced the CDR3 regions of immunoglobulin-coding mRNAs, which revealed that CD20 + TILs are oligoclonal and have undergone somatic hypermutation. 3 Similar results Drawing from the transplantation and autoimmunity fields, we considered several mechanisms to explain how CD20 + TILs could increase patient survival. Initially, we asked whether CD20 + TILs might be a source of tumor-specific serum autoantibodies, which are commonly found in patients. 5 Curiously, we found no association between CD20 + TILs and serum autoantibodies against two common tumor-associated antigens, NY-ESO-1 and p53. 3 Therefore, it appears that CD20 + TILs are not the main source of tumor-specific serum autoantibodies.
Tumor-infiltrating B cells and T cells
As CD20 + TILs are not responsible for humoral antitumor immunity, we reasoned that they may play a role in cellular immunity. In autoimmunity and transplantation, infiltrating B cells have been associated with tissue destruction and appear to enhance T-cell responses in part by serving as antigen-presenting cells (APCs). 6, 7 Consistent with this, we found that CD20 + TILs express molecules associated with APCs, including MHC Class I and II, CD80, CD86 and CD40. 3 Moreover, by multicolor immunohistochemistry, we often found CD20 + TILs to localize with CD8 + T cells in loose aggregates within and adjacent to tumor islets. 3 Similar "tertiary lymphoid structures" have been reported in autoimmunity, allograft rejection and chronic infection. 8 Thus, CD8
+ and CD20 + TILs co-localize in a pattern that is consistent with APC function.
These observations suggest that CD8 + and CD20 + TILs might work together to promote antitumor immunity and patient survival. We assessed this question by comparing survival in patients whose tumors contained CD8 + TILs with or without CD20 + TILs. Importantly, the presence of both CD8 + and CD20 + TILs was associated with markedly increased survival compared with CD8 + TILs alone or no TILs. 3 Collectively, our study provides strong evidence, albeit indirect, that CD8 + and CD20 + TILs act cooperatively to promote antitumor immunity.
How might CD20 + TILs help promote superior antitumor immunity? We propose three possibilities (Fig. 1) . First, by serving as APCs, CD20 + TILs might facilitate the persistence of CD8 + T cells for long periods. 2 Whereas dendritic cells (DCs) may be well suited to initiate immune responses, protective antitumor immunity requires responses to persist for years. Perhaps CD20 + TILs provide ongoing stimulatory signals that inhibit the development of T-cell anergy or exhaustion. Moreover, B cells have the unique ability to take up specific antigen through we recently reported a novel cooperative relationship between tumor-infiltrating B cells and CD8 + t cells in ovarian cancer, leading to increased patient survival. here, we discuss the mechanisms whereby B cells might enhance cellular immunity, including serving as antigen-presenting cells, organizing tertiary lymphoid structures and secreting polarizing cytokines. the enhancement of both B and t-cell responses may result in more potent and sustained antitumor immunity.
to promote potent T-cell responses over the time frames associated with human cancer.
Looking ahead, what are the key research questions concerning CD20 + TILs? To definitively demonstrate that CD20 + TILs serve as APCs to T cells, it is imperative to identify their cognate antigens. Although two antigens have been identified in breast cancer, the antigen repertoire of CD20 + TILs remains largely undefined.
2 New high-throughput screening methods may now make antigen discovery more feasible. There is also an urgent need for understanding the functional profiles of CD20 + TILs. In HGSC, these cells show many of the hallmarks of memory B cells. However, they lack the canonical memory marker CD27, 3 a B-cell phenotype that is also observed in other pathological conditions such as systemic lupus erythematosus. This suggests that CD20 + TILs might have unique functional properties that warrant further study. Of key importance will be to define factors that facilitate the development of coordinated CD8
+ and CD20 + TIL responses. With an improved understanding of these issues, it should be possible to design immunotherapies that enhance not only CD8 + T cell immunity against cancer, but also the potent contributions of CD20 + TILs.
cell depletion with rituximab disrupts T-cell infiltrates in affected tissues. 9 Third, B cells can produce cytokines that polarize T cells toward Th1, Th2 and maybe other functional phenotypes. 10 In summary, several unique properties of B cells might make them ideally suited their surface Ig molecules. This may allow concentration of low-level tumor antigens for processing and presentation to T cells. Second, B cells can produce cytokines such as lymphotoxin that promote the organization of local lymphoid structures. 6 Indeed, in autoimmunity, B 
